
Gemtuzumab ozogamicin for acute myeloid leukemia
2017年11月30日 · On 1 September 2017, the US Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33 + acute myeloid leukemia and for patients aged ≥2 years with CD33 + acute myeloid leukemia who have experienced a relapse or who have not responded to initial treatment. This signals a new ...
肿瘤免疫靶点 | CD33 - 知乎 - 知乎专栏
Gemtuzumab ozogamicin (GO,辉瑞,CD33单抗+N-乙酰-卡奇霉素)是目前唯一获批上市靶向CD33的抗体药物。 (数据来源Walter RB, et al. Blood. 2012) GO曾在2000年就获得FDA批准(第一款获批的ADC药物),不过后期辉瑞因该产品的安全性和在临床试验中缺乏临床效益,于2010年撤回,然后以较低的给药剂量对GO进行重新设计临床试验(在第1、4、7天给予GO诱导剂量为3mg/m2,之前是在第1和14天为9mg/m2),降低了肝静脉闭塞性疾病和早期死亡风险, …
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid …
Gemtuzumab ozogamicin (GO), a humanized murine IgG4 anti-CD33 antibody, is the first target therapy approved in AML therapeutic scenario. This review focuses on current biological information and clinical data from several studies investigating the use …
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33 …
In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML). This is a very significant step toward ...
Gemtuzumab ozogamicin and novel antibody-drug conjugates in …
2019年10月31日 · Single-agent GO is effective and safe for AML patient ineligible for intensive chemotherapy. Multiple combination regimens incorporating GO have also been recommended as potential alternative options. In addition, several novel ADCs targeting CD33, CD123 and CLL-1 are currently undergoing preclinical or early clinical investigations.
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33 …
In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML). This is a very significant step toward defining new treatment regimens in AML, as the treatment …
血液肿瘤靶点-CD33/Siglec-3 - 专注肿瘤免疫
2024年8月16日 · Gemtuzumab ozogamicin(GO,辉瑞,CD33 单抗 +N- 乙酰 – 卡奇霉素)是目前唯一获批上市靶向CD33的抗体药物。 GO 曾在 2000 年就获得 FDA 批准(第一款获批的 ADC 药物),不过后期辉瑞因该产品的安全性和在临床试验中缺乏临床效益,于 2010 年撤回,然后以较低的给药剂量对 GO 进行重新设计临床试验(在第1、4、7天给予GO诱导剂量为 3mg/m2,之前是在第1和14天为 9mg/m2),降低了肝静脉闭塞性疾病和早期死亡风险,2017 年 FDA 重新 …
吉妥珠单抗在CD33阳性急性髓系白血病中的研究进展
吉妥珠单抗(gemtuzumab ozogamicin,GO)是一种由人源化抗CD33单抗与脱氧核糖核酸(deoxyribonucleic acid,DNA)嵌入剂卡奇霉素(calicheamicin,CLM)形成的抗体偶联药物。 CD33表达于90%的AML细胞表面,不表达于正常造血干细胞和成熟粒细胞。 因此,其成为AML靶向治疗的良好靶点。 已有许多研究报道,GO无论是单药还是联合治疗,均能改善CD33阳性AML患者的预后。 本文主要就GO的特征及其在CD33阳性AML中的研究进展进行综述。
当患者接受2 mg/m2以上的GO时, CD33可达90%以上的饱和度,且在第1次用药后72 h 内,CD33可以在细胞表面快速循环和重新表达[4, 9]。 因此,3 d接受1次低剂量GO治疗可以使CD33受 体饱和度维持在90%以上,与14 d接受1次大剂量 给药相比,前者抗白血病活性和安全性 …
Gemtuzumab ozogamicin in acute myeloid leukemia | Leukemia
2017年6月13日 · Efforts to target CD33 therapeutically have focused on gemtuzumab ozogamicin (GO; Mylotarg), an antibody-drug conjugate delivering a DNA-damaging calicheamicin derivative. GO is most...